Posttest - Tumor Board Tuesday - March 1, 2022 (ID: i788-25)

Question Title

* 1. Please list your first name, last name, and email:

First name:

Last name:

Email:

Question Title

* 2. What is your specialty?

Question Title

* 3. Why are pNETs more inherently sensitive to alkylating agents (CAPTEM) vs other NETs?

High percent of MGMT loss

High percent of BRCA/PALB2/ATM mutation

pNETs are not chemosens

High percent of MMR deficiency

Question Title

* 4. Which therapy is approved by the FDA for the treatment of MSS TMB low pNETs irrespective of SSTR expression?

Pembrolizumab

Nivolumab + ipilimumab

Everolimus

Peptide receptor radionuclide therapy (PRRT) with lutetium dotatate